Healthcare -
Biotechnology - NASDAQ - US
$ 21.73
0.509 %
$ 1.25 B
Market Cap
-8.42
P/E
1. INTRINSIC VALUE
Balance Sheet
Structure Therapeutics Inc.
| Current Assets | 891 M |
| Cash & Short-Term Investments | 884 M |
| Receivables | 0 |
| Other Current Assets | 7.69 M |
| Non-Current Assets | 12.1 M |
| Long-Term Investments | 0 |
| PP&E | 7.01 M |
| Other Non-Current Assets | 5.11 M |
| Current Liabilities | 36 M |
| Accounts Payable | 8.02 M |
| Short-Term Debt | 1.7 M |
| Other Current Liabilities | 26.3 M |
| Non-Current Liabilities | 2.47 M |
| Long-Term Debt | 2.16 M |
| Other Non-Current Liabilities | 302 K |
EFFICIENCY
Earnings Waterfall
Structure Therapeutics Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 158 M |
| Operating Income | -158 M |
| Other Expenses | -35.7 M |
| Net Income | -123 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Structure Therapeutics Inc.
| Net Income | -123 M |
| Depreciation & Amortization | 992 K |
| Capital Expenditures | -1.29 M |
| Stock-Based Compensation | 18.8 M |
| Change in Working Capital | 2.96 M |
| Others | -17.2 M |
| Free Cash Flow | -118 M |
Wall Street Analysts Price Targets
Structure Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for GPCR of $99 , with forecasts ranging from
a
low of
$86 to a high of $118 .
GPCR Lowest Price Target
Wall Street Target
86 USD
295.77%
GPCR Average Price Target
Wall Street Target
99 USD
355.59%
GPCR Highest Price Target
Wall Street Target
118 USD
443.03%
4. DIVIDEND
ANALYSIS
GPCR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Structure Therapeutics Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.
globenewswire.com
- 1 week ago
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
zacks.com
- 2 months ago
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.
benzinga.com
- 2 months ago
Structure Therapeutics CEO on latest GLP-1 developments
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.
youtube.com
- 3 months ago
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge.
seekingalpha.com
- 3 months ago
Why Structure Therapeutics Stock Was Stumbling This Week
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
fool.com
- 4 months ago
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
globenewswire.com
- 5 months ago
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan has reset the valuation for Viking Therapeutics Inc. VKTX and Structure Therapeutics Inc. GPCR.
benzinga.com
- 5 months ago
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
globenewswire.com
- 6 months ago
Structure CEO on the competitive landscape for oral GLP-1 drugs
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
youtube.com
- 6 months ago
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
benzinga.com
- 7 months ago
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
globenewswire.com
- 7 months ago
8. Profile
Summary
Structure Therapeutics Inc. GPCR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.25 B
Dividend Yield
0.00%
Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Contact
611 Gateway Boulevard, South San Francisco, CA, 94080
https://structuretx.com
IPO
Date
Feb. 3, 2023
Employees
163
Officers
Dr. Blai Coll M.D., Ph.D.
Chief Medical Officer
Mr. Jun S. Yoon
Co- Founder, Chief Financial Officer & Secretary
Dr. Yingli Ma Ph.D.
Chief Technology Officer
Mr. Bob Gatmaitan
Senior Vice President of People
Dr. Raymond C. Stevens Ph.D.
Chief Executive Officer & Director
Mr. Tony Peng
Senior Vice President of Legal
Ms. Lani Ibarra
Senior Vice President of Clinical Development Operations
Dr. Hui Lei Ph.D.
Senior Vice President of Chemistry
Dr. Xichen Lin Ph.D.
Chief Scientific Officer
Dr. Fang Zhang Ph.D.
Executive Vice President & Head of Biology